$DHR

Blair Rainer sold $12.7M of DHR (indirect holdings)

Blair Rainer (President & CEO) sold 58,255 indirectly-held shares of DANAHER CORP /DE/ (DHR) at an average of $218.63 ($217.77–$219.35, $12.74M total) across 3 trades on 2026-08-21.

Original reporting
SEC EDGAR · Blair Rainer
Published Aug 24, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 24, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$DHR
Bearish
medium confidence
Mentioned
$DHR
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DHRBearishLow
01

Why it matters

The sale reduces insider ownership to zero, potentially affecting investor perception of confidence.

02

Market read

Direct impact on DHR stock; limited broader market effect.

03

What to watch

No 10b5‑1 plan; sale may be tax‑driven or personal liquidity need.

Relevance 7/10Novelty 7/10Timing: filing released on 2026-08-24

Background

Form 4 filings disclose insider transactions; large executive sales are closely watched.

Company-level read

Ticker impact

$DHRBearishMedium confidence
Context

President & CEO Blair Rainer sold 58,255 shares for $12.7M, reducing his stake to zero.

Expected impact

Potential short-term dip of 1-2% as market digests the sale.

Evidence & confidence

Sale size is material for a large-cap; insider is top executive, but no pre‑arranged plan disclosed.

Market effects

May prompt scrutiny of Danaher governance but limited sector impact.

U.S. market focus; no broader regional effect.

Minimal global relevance beyond Danaher investors.

Counterpoint

Insider sell could be routine diversification, not a negative signal.

Key entities

  • Blair Rainer

    President & CEO of Danaher Corp.

  • Danaher Corp.

    Global science and technology conglomerate.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DHRMedAI 8/10

Danaher vs. Intuitive Surgical: Is Recovery or Innovation the Better Long-Term Bet?

Danaher (DHR) and Intuitive Surgical (ISRG) present contrasting growth paths. Danaher benefits from improving life sciences spending, with strong bioprocessing orders and $100M revenue shifted to next year. Intuitive Surgical reports 18% YoY growth in da Vinci system placements, 70% non-GAAP gross margin, and 85% recurring revenue. Investors must decide between cyclical recovery and structural growth.

$DHRMedAI 8/10

Danaher vs. Medtronic: Which Healthcare Recovery Story Has More Upside?

Danaher (DHR) and Medtronic (MDT) report recovery signs. DHR benefits from life sciences demand, with bioprocessing orders growing mid-teens. MDT shows highest annual revenue growth in 10 years, with Q4 revenue at $9.8B and FY26 at $36.4B. MDT's cardiac segment grew 78% globally, driven by cardiac ablation solutions. Both companies face challenges, with MDT's growth concentrated in a few platforms and DHR's revenue delayed into next year.

$DHRMed

Danaher shareholders applaud new CEO pick

Danaher said its board selected Julie Sawyer Montgomery as President and CEO effective Oct 1, 2026. According to the company, she helped grow its Diagnostics platform revenue to about $11B from about $6B and tripled operating profit. Danaher also said Q3 and full-year 2026 guidance is unchanged and outgoing CEO Rainer Blair stays as senior advisor through Mar 31, 2027.

$DHRMed

Danaher stock rises after naming new CEO, backing guidance

Danaher (NYSE:DHR) shares rose about 2% after hours after the company named Julie Sawyer Montgomery as President and CEO effective Oct. 1, 2026, succeeding Rainer Blair. Danaher also reaffirmed its previously issued Q3 and full-year 2026 guidance. Montgomery led the Diagnostics platform, growing revenue from about $6B in 2017 to about $11B.